VIVUS

Will Novo’s big thinking in obesity pay off?

Novo Nordisk has high hopes that obesity will become a major source of sales, and data on the company’s most promising projects are looming.

January 28, 2020

Acceleron’s post-Reblozyl plan comes together

Sotatercept’s win in pulmonary arterial hypertension positions Acceleron for a battle against the leaders in this crowded space.

November 29, 2018

FDA decision time looms for Gelesis

Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?

August 28, 2018

Data point - How slimming down is growing up

March 14, 2018

Debt comes back to haunt biotech

March 07, 2018

Interview – Novo fattens up its obesity pipeline

August 14, 2017

The balloon goes up for Apollo and Reshape

July 20, 2016

The end of another chapter in obesity drug development

January 04, 2016

Pharma regulatory and development news over Christmas

August 07, 2015

Orexigen trades one problem for another

July 30, 2015

The skinny on treating obesity – devices vs drugs

Load More